FDA workshop on ANDA deficiencies
Executive Summary
Scheduled for Sept. 24 at the Parklawn Building conference rooms D & E to provide guidance to industry on improving ANDAs. FDA will present preliminary results of study by Evaluation and Analysis staff on chemistry and manufacturing deficiencies found in ANDA submissions. According to Staff Director Douglas Sporn, FDA evaluated a random sample of ANDAs that generated at least two deficiency letters. A total of 1,200 deficiencies, including chemistry, manufacturing and labeling, were found in the 45 ANDAs selected. The completed study may be released before the end of October. The workshop will also include discussion on the Office of Generic Drugs Policy and Procedure Guides.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.